The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
Phase 3 – large-scale trial before approval
Conditions:
Asthma with type 2 inflammation characterized by an eosinophilic phenotype
Sponsor: Glaxosmithkline Research & Development Limited
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline in airway wall thickness measured at TLC at Week 52.
Change from baseline in total mucus plug volume measured at TLC at Week 26
Description
Change from baseline in airway wall thickness measured at TLC at Week 52.
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 55 participants
БГ